Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction

PHASE3CompletedINTERVENTIONAL
Enrollment

3,491

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions
Acute Coronary Syndromes
Interventions
DRUG

Clopidogrel (SR25990)

plus acetylsalicylic acid (ASA)

DRUG

Placebo

plus acetylsalicylic acid (ASA)

Trial Locations (24)

08807

Sanofi-Aventis, Bridgewater

Unknown

Sanofi-Aventis, Buenos Aires

Sanofi-Aventis, Macquarie Park

sanofi-aventis Austria, Vienna

sanofi-aventis Belgium, Diegem

sanofi-aventis Brazil, São Paulo

sanofi-aventis Canada, Laval

sanofi-aventis France, Paris

sanofi-aventis Germany, Berlin

Sanofi-Aventis Hungaria, Budapest

Sanofi-Aventis, Dublin

Sanofi-Aventis, Netanya

sanofi-aventis Italy, Milan

Sanofi-Aventis Mexico, México

sanofi-aventis Netherlands, Gouda

sanofi-aventis Poland, Warsaw

Sanofi-Aventis, Porto

Sanofi-Aventis, San Juan

Sanofi-Aventis, Moscow

sanofi-aventis South Africa, Midrand

sanofi-aventis Spain, Barcelona

sanofi-aventis Sweden, Bromma

Sanofi-Aventis, Istanbul

sanofi-aventis UK, Guildford

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sanofi

INDUSTRY

NCT00714961 - Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction | Biotech Hunter | Biotech Hunter